お気に入りに追加
製品詳細
Synonyms
B7-H4, VTCN1, B7S1, B7h.5
Source
Human B7-H4 Protein, Fc Tag (B74-H5256) is expressed from human 293 cells (HEK293). It contains AA Phe 29 - Ala 258 (Accession # Q7Z7D3-1).
Predicted N-terminus: Phe 29
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.8 kDa. The protein migrates as 66-85 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
お客様はこちらも閲覧
データ表示
SDS-PAGE
Human B7-H4 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human B7-H4 Protein, Fc Tag (Cat. No. B74-H5256) at 0.5 μg/mL (100 μL/well) can bind Anti-B7-H4 MAb (Human IgG1) with a linear range of 0.2-8 ng/mL (QC tested).
Protocol
ユーザーレビュー コメントを投稿
バックグランド
最新の進展
医薬品開発の進捗- 英語名：
V-set domain-containing T-cell activation inhibitor 1
- カテゴリ：
- 市販の医薬品数：
0 詳細
- 治験医薬品数：
11 詳細
- 最新の開発ステージ：
Phase 3 Clinical
お問い合わせ
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
医薬品候補ライセンス
